TwoStep Therapeutics, a biotechnology company spun out of Stanford University research, has announced a significant milestone: its lead peptide-drug conjugate has cleared the FDA’s Investigational New Drug (IND) review, clearing the path for human clinical trials. The news arrives alongside a fresh $62.5 million funding round, giving the company substantial resources to advance its pipeline of peptide-based therapeutics.
Peptide-drug conjugates represent one of the more promising frontiers in targeted medicine. By pairing a peptide that can precisely home in on specific cell types with a therapeutic payload, these conjugates aim to deliver treatment directly where it’s needed while potentially sparing healthy tissue from unnecessary exposure. This approach builds on lessons learned from antibody-drug conjugates but leverages the smaller size, tunability, and manufacturing advantages that peptides can offer.
The successful IND clearance is a meaningful regulatory milestone, indicating that the FDA has reviewed TwoStep’s preclinical data on safety and manufacturing quality and deemed the program ready to proceed into initial human studies. For a Stanford-originated biotech, this transition from academic research to clinical-stage development reflects years of foundational science translating into a tangible therapeutic candidate.
The $62.5 million raise gives TwoStep the capital needed to move its lead program through early-phase clinical trials while continuing to build out its broader peptide conjugate platform. Strong investor backing at this stage often signals confidence not just in a single drug candidate, but in the underlying technology’s potential to generate additional therapeutic programs down the line. For the peptide therapeutics field more broadly, this kind of investment and regulatory progress helps validate the growing interest in peptide-based conjugation strategies as a complement to more established biologic drug classes.
As TwoStep prepares to enter clinical trials, the coming months should bring more clarity on the specific disease area being targeted and the design of initial studies. Milestones like this help expand the toolkit available to researchers and, potentially, to patients in the future. This article is for informational purposes only and is not medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Stanford spinout TwoStep raises USD 62.5m as lead peptide-drug conjugate clears FDA IND – AllSci
Leave a Reply